{
  "docId": "019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "docSlug": "7a45cce2c7eb1605e2a52f1d1ebe6b6d",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 20 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 20,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de515-bf16-778d-9d2b-a6c6e17ebc6c/15",
  "deckHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "deckJsonHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c.json",
  "deckAnchorHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.402,
        "w": 0.202,
        "x": 0.218,
        "y": 0.27
      },
      "kind": "image",
      "text": null,
      "attrs": {},
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1e2695a-3da2-400d-bf9a-3fd32e3a946f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.16,
        "x": 0.037,
        "y": 0.875
      },
      "kind": "image",
      "text": null,
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ea09cf3-0d52-4a69-9014-6b9ce522601b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.279,
        "w": 0.22,
        "x": 0.675,
        "y": 0.207
      },
      "kind": "list",
      "text": "Gene-Editing Tools used in\nMaxCyte-Enabled Clinical Trials\nARCUS\nBase-editing (CRISPR)\nCRISPR\nRNA-Based Engineering\nTALENS\nZinc Finger Nucleases (ZFNs)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5cb8fe9-5731-4b4d-8668-d609d505c07b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.601,
        "w": 0.602,
        "x": 0.037,
        "y": 0.183
      },
      "kind": "list",
      "text": "Indications in Active MaxCyte-Enabled Clinical Trials\nGenetic Diseases\nBeta-Thalassemia\nSickle Cell Disease\nChronic Granulomatous Disease (CGD)\nHematological Malignancies\nAcute Lymphoblastic Leukemia\nAcute Myeloid Leukemia\nChronic Lymphocytic Leukemia\nMultiple Myeloma\nNon-Hodgkin Lymphoma\nT-Cell Lymphoma\nInfectious Disease\nHIV\nSolid Tumors\nNon-small Cell Lung Cancer\nGlioblastoma\nRenal Cell Carcinoma\nOther Solid Tumors",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8f5883f-3c6e-4dcc-a5dc-432ffbc64fdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.19,
        "x": 0.271,
        "y": 0.69
      },
      "kind": "metric",
      "text": "1,000+",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f884463-840a-42f6-bfdd-0ef4e3294036",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.204,
        "x": 0.698,
        "y": 0.69
      },
      "kind": "metric",
      "text": "2023/2024",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef5ca62f-a759-44b2-a24a-878698b65301",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.26,
        "x": 0.66,
        "y": 0.579
      },
      "kind": "paragraph",
      "text": "First MaxCyte-Enabled Therapy is\nexpected to be approved as early as",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c092116-f7cd-4902-9003-d6bb0741a080",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.014,
        "w": 0.359,
        "x": 0.17,
        "y": 0.768
      },
      "kind": "paragraph",
      "text": "Estimated patients in active clinical trials enabled by MaxCyte",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d88fafa0-fdb8-4acc-bf50-b75a530d7f2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.012,
        "w": 0.136,
        "x": 0.745,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d2ebfc2-2db3-40ad-9f42-692db4fcaa26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.012,
        "w": 0.434,
        "x": 0.037,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "As of March 2023 / Includes Commercial and Academic Clinical Trials. Source: clinicaltrials.gov",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "539c7636-e21e-4961-9362-9e5d593dca9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.012,
        "w": 0.15,
        "x": 0.823,
        "y": 0.962
      },
      "kind": "source-note",
      "text": "© 2023 MaxCyte, Inc. All Rights Reserved",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77f33126-64fe-4532-9f55-6b2ae3996e01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.012,
        "w": 0.018,
        "x": 0.49,
        "y": 0.962
      },
      "kind": "source-note",
      "text": "15",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9edb28e-f559-4f16-a4cd-7cd3aebfb1eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.926,
        "x": 0.042,
        "y": 0.075
      },
      "kind": "title",
      "text": "MaxCyte Enables Next-Generation Cell Therapies Across a Variety of Diseases",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93b941e2-a1ea-4c6a-af20-e09f8d057acd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1b37bf2a-4731-4886-81e1-dbaaf7521786",
      "evidence": "The deck presents the benefits of MaxCyte's technology and the limitations of current methods.",
      "position": 0,
      "objective": "What are the consequences of not adopting MaxCyte's technology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}